A phase 3, multicenter, open-label study of naldemedine in cancer patients with opioid-induced constipation - extension study

Trial Profile

A phase 3, multicenter, open-label study of naldemedine in cancer patients with opioid-induced constipation - extension study

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs Naldemedine (Primary)
  • Indications Constipation
  • Focus Adverse reactions
  • Sponsors Shionogi
  • Most Recent Events

    • 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 06 Jun 2016 According to a Shionogi media release, the New Drug Application (NDA) submitted in the U.S. for naldemedine, a once-daily, oral 0.2 mg tablet, has been accepted for review and the target action date under the Prescription Drug User Fee Act (PDUFA) is March 23, 2017.
    • 20 Jan 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top